Under this partnership, Antheia will leverage TAPI's next-generation fermentation capabilities and manufacturing facilities in Europe to further commercialise its pipeline of biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs).
Antheia | 21/11/2025 | By Dineshwori
Antheia Appoints Richard Sherwin as Head of Commercialization
Antheia Appoints Richard Sherwin as Head of Commercialization
Antheia | 18/08/2023 | By Sudeep Soparkar | 853
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy